The high level of IL-1 beta in the serum of ACLF patients induces increased IL-8 expression in hUC-MSCs and reduces the efficacy of hUC-MSCs in liver failure

Background Stem cells play a therapeutic role mainly through immunoregulation. However, the immunomodulatory function of stem cells may be affected by inflammation-related factors in patients' serum. Therefore, this study aims to investigate the possible mechanism by which acute-on-chronic liver failure (ACLF) patient serum influences the efficacy of hUC-MSCs. Methods The serum of surviving and dead ACLF patients was collected to culture hUC-MSCs in vitro, and the hUC-MSCs cultured in the serum of ACLF patients were used to treat acute liver failure (ALF) rats. The therapeutic effect on the rats was evaluated by a survival curve, the transaminase level and liver histopathology. The expression of cytokines in hUC-MSCs was detected by Q-PCR and ELISA. Results Serum pretreatment reduced the therapeutic effect of hUC-MSCs on ALF, especially pretreatment in the serum from dead ACLF patients. After hUC-MSCs were cultured in the serum of surviving or dead ACLF patients, the most differentially expressed factor was IL-8. Interfering with the expression of IL-8 in hUC-MSCs can improve the therapeutic effect of hUC-MSCs on ALF. The high level of IL-1 beta in the serum of dead ACLF patients causes the increased expression of IL-8 in hUC-MSCs through the activation of the NF-kappa B signaling pathway. Meanwhile, we found that the neutralizing IL-1 beta in serum from dead ACLF patients can improve the therapeutic effect of hUC-MSCs on ALF. Conclusion The high level of IL-1 beta in ACLF serum can promote the expression of IL-8 in hUC-MSCs through the NF-kappa B signaling pathway, thus reducing the effect of hUC-MSCs on ALF.

Automated summary

This study explores the mechanism by which the serum of ACLF patients affects the therapeutic efficacy of hUC-MSCs. It is found that inflammation-related factors in ACLF serum can reduce the immunomodulatory function of hUC-MSCs through the NF-kappa B signaling pathway, specifically by promoting the expression of IL-8 in hUC-MSCs, thus compromising their therapeutic effect on ALF.